Studies a dissolving heart stent in people with coronary artery disease
Checks the safety and performance of a dissolving stent in adults with heart artery disease.
Key facts
- Who runs it
- Elixir Medical Corporation
- Where
- Amman, JordanSee the 2 sitesAlso in 8 other countries, 15 sites
- Trial code
- Registry title
- DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System
- Status
- Recruiting
- People taking part
- 5,000 people, planned
- Started
- 10 Mar 2024
- Expected to end
- Dec 2028
- Type of study
- Observational
- Treatments tested
- DynamX Novolimus-eluting Coronary Bioadaptor System
- Record updated
- 28 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with coronary artery disease who are having a stent placed and will receive at least one DynamX Bioadaptor implant.
- Age
- Over 18 years
- Sex
- All sexes can join.
- Disease stage
- Coronary artery disease where a procedure with stent implantation (PCI) is planned.
- Earlier treatment
- People with earlier venous or arterial bypass grafts cannot join.
Main reasons for not taking part
- Target lesion in the left main artery
- Earlier venous or arterial bypass grafts
- In-stent restenosis
- Taking part in another trial with an investigational device or drug that has not yet reached its main endpoint
- Unable to follow the trial rules, in the investigator's opinion
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Over 18 years of age
- Patient understands the trial requirements and treatment procedures and provides informed consent
- Patient indicated for PCI with stent implantation and receive at least one DynamX Bioadaptor implant in accordance with the product's Instructions for Use (IFU)
Who cannot take part
- Prior venous or arterial bypass grafts
- Patient is currently participating in another clinical trial with an investigational device or an investigational drug that has the potential to impact study results (e.g., anti-thrombotic or anti-platelet medications) that has not yet completed its primary endpoint
- Target Lesion(s) in the left main artery
- In-stent restenosis
- Patient is, in the opinion of the Investigator, unable to comply with the requirements of the study protocol or is unsuitable for the registry for any reason
Where in Jordan
Also in 8 other countries, 15 sites
- Jordon HospitalAmman, JordanContact: Imad Alhaddad, MDTaking people
- The Specialty HospitalAmman, JordanContact: Mazen Sudqi, MDTaking people
About the trial
What the trial wants to find out
The goal of this registry is to confirm the safety, and performance of the DynamX Coronary Bioadaptor System in patients with coronary artery disease.
The group in the trial
- Open Label
DynamX Novolimus-eluting Coronary Bioadaptor System
Treatment: DynamX Novolimus-eluting Coronary Bioadaptor System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System (Bio-RESTORE)
- Plain-language title
- Studies a dissolving heart stent in people with coronary artery diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 August 2025